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Abstract
Background: The purpose of this study was to review the reported associations of depression and antidepressants
with motor vehicle crashes.
Purpose: A literature search for material published in the English language between January, 1995, and October, 2015,
in bibliographic databases was combined with a search for other relevant material referenced in the retrieved articles.
Methods: Retrieved articles were systematically reviewed for inclusion criteria: 19 epidemiological studies
(17 case-control and 2 cohort studies) fulfilled the inclusion criteria by estimating the crash risk associated
with depression and/or psychotropic medications in naturalistic settings.
Results: The estimates of the odds ratio (OR) of crash involvement associated with depression ranged from
1.78 to 3.99. All classes of antidepressants were reported to have side effects with the potential to affect
driving safety. The majority of studies of antidepressant effects on driving reported an elevated crash risk,
and ORs ranged from 1.19 to 2.03 for all crashes, and 3.19 for fatal crashes. In meta-analysis, depression was
associated with approximately 2-fold increased crash risk (summary OR = 1.90; 95% CI, 1.06 to 3.39), and antidepressants
were associated with approximately 40% increased crash risk (summary OR = 1.40; 95%CI, 1.18 to 1.66).
Conclusion: Based on the findings of the studies reviewed, depression, antidepressants or the combination of
depression and antidepressants may pose a potential hazard to driving safety. More research is needed to
understand the individual contributions of depression and the medications used to treat depression.
Keywords: Crashes, Driving, Depression, Antidepressants, Intentional crashes
Review
Background
Motor vehicles crashes are a leading cause of death in
the U.S. with 32,675 fatalities reported in 2014, and an
8% increase in the first half of 2015 (National Highway
Traffic Safety Administration. Data: NHTSA [Internet]
2015). Both medical conditions and medications have
the potential to impair the ability to safety operate a
motor vehicle (Meuleners et al. 2006; Zuin et al. 2002).
The crash risk has been reported to increase with in-
creasing numbers of daily medications (LeRoy & Morse
2008; Monarrez-Espino et al. 2014). Depression is a
highly prevalent and underdiagnosed (Centers for
Disease Control and Prevention 2010; Mitchell et al.
2009) condition. It affects nearly 10% in the adult
population, and has a lifetime prevalence of approxi-
mately 13% (Hasin et al. 2005; Patten et al. 2006). Psy-
chomotor retardation can be a manifestation of
depression and may potentially influence driving safety
(Sherwood 1995; Austin et al. 2001; Bulmash et al.
2006). Antidepressants as a group are the second most
commonly prescribed drug classes (Aitken 2014). Anti-
depressants may alleviate the symptoms of depression,
but they may be associated with side effects that could
impair driving (Sherwood 1995).
The purpose of this study was to review the reported
effects of depression and antidepressants on motor
vehicle crash risk. The diagnosis and treatment of de-
pression has changed significantly over the last 40 years.
This paper includes epidemiologic studies conducted in
the last 20 years since the publication of the Diagnostic
and Statistical Manual of Mental Disorders, 4th Edition* Correspondence: llhill@ucsd.edu
1Department of Family Medicine and Public Health, San Diego, USA
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(DSM-IV) in 1994. Experimental studies, mainly using
driving simulators, were not included in this review.
Methods
Eligibility
Studies were included if they (National Highway Traffic
Safety Administration. Data: NHTSA [Internet] 2015)
examined the association between depression or anti-
depressant use and motor vehicle crash risk; (Meuleners
et al. 2006) used an epidemiologic design (e.g., cohort,
case control, and case-crossover), and (Zuin et al. 2002)
were published in English between January, 1995, and
October, 2015. Cross-sectional studies, qualitative stud-
ies, reviews, commentaries, opinion pieces, and maga-
zine articles were excluded. In this review, depression
was ascertained through questionnaires such as the
Geriatric Depression Scale (GDP), General Health Ques-
tionnaire (GHQ) or their modified versions, as well as
interviews and claims-based databases. Antidepressants
included classes of medications prescribed for the
treatment of depression such as tricyclics (e.g. amitrip-
tyline, imipramine), monoamine oxidase inhibitors
(MAOI) (, e.g. phenelzine, tranylcypromine), selective
serotonin reuptake inhibitors (SSRI) (, e.g.citalopram,
escitalopram), serotonin-norepinephrine reuptake in-
hibitors (SNRI )(e.g.venlafaxine, duloxetine), and atypi-
cals (e.g. bupropion, mirtazapine).
Search Strategy and Data Extraction
Relevant articles were identified through a comprehen-
sive search of the research literature. Electronic data-
base searches included PubMed (1995-October, 2015),
Medline Plus (1995-October, 2015), Google Scholar
(1995-October, 2015), Ingenta Connect (1995-October,
2015), and grey literature databases. One author (LH)
conducted the initial search and screened study titles
and abstracts using the inclusion and exclusion criteria.
Other authors (SC, KL, EW) independently searched
for relevant studies and collected and recorded data
used to estimate odds ratios from eligible studies. For
each included study, information on author, year of
publication, study sample, study design, country, study
period, and findings were noted.
Quality Assessment and Data Analysis
All studies that met the inclusion criteria were assessed
for quality using the Newcastle-Ottawa Scale (NOS)
(Wells et al. 2015) as recommended by the Cochrane
Collaboration on bias assessment (Higgins & Green S.
Cochrane Handbook for Systematic Reviews of Interven-
tions Version 5.1.0 [updated March 2011). For the study
designs included in this study, the best possible score is
9. Better quality studies will have higher scores. Hetero-
geneity was assessed using the Q and I2 tests, with
P ≤ .05 and I2 > 0.5 considered homogenous. Funnel
plots were used to assess publication bias. Data
abstracted from each study were entered in the Compre-
hensive Meta-Analysis software (Borenstein et al. 2005)
to compute the individual odds ratios and a summary
odds ratio for each of the two analyses. A fixed effects
model was used unless heterogeneity was present, in
which case, a random-effects model would be preferred.
Two forest plots were created; one to show the distribu-
tion of the effect of depression on car crash risk (Fig. 1)
and another one to show the distribution of the effect of
antidepressant use on car crash risk (Fig. 2).
Results
The effect of depression on driving and crashes
Seven studies investigating the effect of depression on
driving met the inclusion criteria (Table 1). Rainio et al
(Rainio et al. 2007) conducted a retrospective review of
crashes in 2001 and 2002, using interviews of police, sur-
viving drivers, and family members, medical records,
and autopsy reports. A physician on the team made the
determination of the presence of depression. This
Finnish study used the reports of the road crash investi-
gation teams which investigate every fatal crash in
Finland. Of the 640 crash deaths analyzed, 390 were
Fig. 1 Forest plot, summary odd ratio and 95% confidence of association of risk of car crashes with depression. The summary odds ratio is
indicated by the diamond. Horizontal bars indicate the 95% confidence intervals
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drivers considered to be at fault. Of these 390, 6.4% had
depression, while one non-fault driver and none of the
non-fault passengers had depression (Rainio et al. 2007).
No medication data were included in the analysis.
Sagberg (Sagberg 2006) used self-report questionnaires
from 4448 crash-involved drivers in Norway and found
an OR of 2.43 in persons reporting depression. Though
antidepressants were included, the relationship between
antidepressants and depression was not included in the
analysis. Mann et al (Mann et al. 2010) did a cross-
sectional telephone survey of adults in Ontario, Canada
aged 18 and older. Depression and anxiety were deter-
mined using two subscales of the 12-item General
Health Questionnaire: Depression-anxiety and social
functioning. With a sample of 4935 adults, Mann et al
(Mann et al. 2010) found the odds of crash involvement
increased significantly with an increase in the anxiety/
depression score, with a five percent increase in the risk
of crash involvement for every unit of anxiety/depression
increase (95% CI, 1.01 to 1.09). Medications for depres-
sion were not included in the study. Wickens et al
(Wickens et al. 2013), also with an Ontario sample of
12,830, studied self-reported anxiety and mood disor-
ders, queried via telephone survey, and found an in-
crease in crashes (OR = 1.78; 95% CI, 1.37 to 2.31).
There was no report of antidepressant use. Sims et al
(Sims et al. 2000), in a prospective analysis of 174
older adults, used baseline and one year follow-up in-
person assessments. They found that a Geriatric
Depression Scale score ≥16 was associated with an in-
creased crash rate (RR =2.53; 95% CI,1.08 to 5.95).
While antidepressant use was assessed, the relation-
ship between depression, antidepressants and crashes
was not reported, and in this study the relationship
between antidepressant use and crashes was not sig-
nificant. LeRoy (LeRoy & Morse 2008) found an OR
of 3.99 for crash risk with depression in a case con-
trol study of 81,408 cases and 244,224 controls (95%
CI, 3.19 to 4.99) using claims-based population data.
Another study of older adults (Margolis (Margolis et
al. 2002)), using the Geriatric Depression Scale,
included depression in their analysis and found no as-
sociation; however, this study was small, with a low
prevalence of depression in the study population
(Margolis et al. 2002; McGwin et al. 2000).
The effect of antidepressants on driving
Ten studies (Table 2) meeting inclusion criteria evalu-
ated the relationship between antidepressants and motor
vehicle crashes. Several studies have used population-
based data sets to assess the risk of antidepressants and
driving (National Highway Traffic Safety Administration.
Data: NHTSA [Internet] 2015; Meuleners et al. 2006;
Aitken 2014; Bramness et al. 2008; Barbone et al. 1998;
Ravera et al. 2011; Gibson et al. 2009; Lam et al. 2005;
Greenblatt et al. 1999). Hooper et al (Hooper et al.
2010) retrospectively studied a U.S. active duty military
population between 2002-2006, using an integrated
health systems database, and found an adjusted OR of
3.19 for the effect of antidepressants on crash risk (95%
CI, 1.01 to 10.07). Depression was not assessed. Orriols
et al (Orriols et al. 2012) did a case-crossover analysis of
72,685 drivers in France using the national health care
insurance database and the national police database and
found an OR of 1.34 for crash and prescription of anti-
depressants as a class (95% CI, 1.22 to 1.47). SSRIs (OR
= 1.30; 95% CI, 1.16 to 1.46), SNRIs (OR = 1.51; 95% CI,
1.25 to 1.84), and other antidepressants (OR = 1.30; 95%
CI, 1.01 to 1.67) also had a significant association with
increased risk of crash. In a different analysis, Orriols et
al (Orriols et al. 2013) studied 109,406 older drivers aged
66-84 years in Quebec, Canada, using provincial police
and health databases. They found that 20% had at least
one prescription of an antidepressant during the study
period, and 2.7% were exposed to antidepressants on the
day of the crash (OR = 1.19; 95% CI, 0.94 to 1.51).
Fig. 2 Forest plot, summary odd ratio and 95% confidence of association of risk of car crashes with anti-depressants. The summary odds ratio is
indicated by the diamond. Horizontal bars indicate the 95% confidence intervals
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Neither of the studies by Orriols included data on de-
pression. Rapaport (Rapoport et al. 2011) did a case-only
time to event analysis in 159,678 persons in Ontario,
also using provincial databases, and found that SSRI and
SNRI antidepressants were associated with at-fault
crashes alone (HR = 1.10; 95% CI, 1.09 to 1.13), in com-
bination with a benzodiazepine (adjusted HR = 1.23; 95%
CI, 1.17 to 1.28), and with an anticholinergic medication
(adjusted HR = 1.63; 95% CI, 1.57 to 1.69). The period
within the first 3-4 months of antidepressant initi-
ation also was associated with increased risk of crash
(Rapoport et al. 2011). Bramness (Bramness et al.
2008), using national databases, found non-sedating
antidepressants increased the risk for traffic crashes
(SIR = 1.6; 95% CI, 1.5 to 1.7) more than sedating an-
tidepressants (SIR = 1.4; 95% CI, 1.2 to 1.6). Neither
Rapaport nor Bramness include depression as a vari-
able. Sagberg (Sagberg 2006), in a Norwegian study of
4,448 crash involved drivers, found the self-reported
use of antidepressants had an adjusted OR for crash
of 1.70 (95% CI, 0.98 to 2.24). While this study, and
the following two studies (LeRoy and Sims) included
both depression and anti-depressants, the relationship
between the two variables was not assessed. LeRoy
(LeRoy & Morse 2008), in a US-based case-control
study of 5,398 cases and 16, 194 controls, using na-
tional survey and also claims-based databases, found
that serotonin-2 antagonist/reuptake inhibitors had an
OR for crash of 1.90 (95% CI, 1.49 to 2.44). Barbone
(Barbone et al. 1998), in a case crossover study in the
UK, used a local prescription database and found no
association between crash and tricyclic or SSRI anti-
depressants in the 1998 study of 19,386 crashes.
Ravera (Ravera et al. 2011) in the Netherlands study
of 3,963 cases and 18,828 controls used three existing
Dutch population-based databases and found an OR
of crash with SSRI of 2.03 (95% CI, 1.31 to 3.14).
Gibson (Gibson et al. 2009), using a primary care
database, found that SSRI had no effect in the short
term (IRR = .92; 99% CI, 0.75 to 1.12), but had a
small increase in the risk of crash with extended use
(IRR = 1.16; 99% CI, 1.06 to 1.28) in a case crossover
study of 49,821 crashes. None of these three studies
included depression as a variable.
Meta-analysis: Depression and car crash risk
Three cohort (Mann et. al (Mann et al. 2010); Margolis
et. al (Margolis et al. 2002); Sims et.al (Sims et al. 2000))
and three case control studies (LeRoy et. al (LeRoy &
Morse 2008); Sagberg (Sagberg 2006); Wickens et. al
(Wickens et al. 2013)) that examined the association be-
tween depression and car crash risk were included in the
quantitative meta-analysis (Table 1). One study (Rainio
et. al (Rainio et al. 2007)) was excluded from the
depression meta-analysis because it assessed aggregate
data on crashes, crash deaths, and depression. Effect es-
timates showed some heterogeneity (Q = 153.741, df = 5,
P = 0.000; I2 = 96.748), hence a random effects model
was used. A funnel plot from the six studies did not in-
dicate any major publication bias. Pooled data from the
six studies indicate that depression nearly doubles the
risk of involvement in a car crash (summary OR = 1.90;
95% CI,1.06 to 3.39) (Fig. 1).
Meta-analysis: Antidepressant use and car crash risk
Three case-crossover (Barbone et.al (Barbone et al.
1998), Gibson et. al (Gibson et al. 2009), Orriols et. al
(Orriols et al. 2013)) and five case control studies
(Hooper et. al (Hooper et al. 2010), LeRoy et. al (LeRoy
& Morse 2008), Ravera et.al (Ravera et al. 2011), Sagberg
et.al (Sagberg 2006), Orriols et. al (Orriols et al. 2012))
were included in the quantitative meta-analysis on anti-
depressant use and crash risk (Table 2). Two studies
(Bramness et. al (Bramness et al. 2008), Rapoport et. al
(Rapoport et al. 2011)) were excluded from the anti-
depressant use meta-analysis because event data could
not be extracted. Effect estimates showed some hetero-
geneity (Q = 47.337, df = 7, P = 0.000; I2 = 85.212), hence
a random effects model was used. The random effects
and the fixed effects model estimates were close. A fun-
nel plot from the six studies did not indicate any major
publication bias. Pooled data from the eight studies
show that antidepressant use may increase the risk of
car crash involvement by 40% (summary OR = 1.40; 95%
CI, 1.18 to 1.66) (Fig. 2).
Discussion
Depression and antidepressants have mental and phys-
ical effects with the potential to adversely affect the abil-
ity to operate a motor vehicle. Depression, in addition to
psychomotor retardation, is often associated with sui-
cidal ideation and intent, increasing the potential for
both unintentional and self-harm related motor vehicle
crashes (Lam et al. 2005). The studies reviewed, con-
ducted mainly in developed countries, found associa-
tions between depression and crashes. Though estimates
are hampered by the variation in study population and
study design, depression was generally found to approxi-
mately double the risk of crash risk.
Antidepressants have numerous side effects that in-
clude drowsiness, hypotension, suicidal ideation, dizzi-
ness, decreased seizure threshold, nausea, and anxiety.
These may individually and combined have the potential
to interfere with driving abilities. Studies of the effects of
antidepressants as a class and driving found a modest in-
crease in crash risk, with OR ranging from 1.19 to 1.90
for crashes, and 3.19 for fatal crashes. The effect varied
by type of antidepressant, with significant variation
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between studies, but averaged about 1.4 times the crash
risk in meta-analysis.
Antidepressants have potentially conflicting contribu-
tions to motor vehicle crashes in relieving the effects of
depression and suicide while posing side effects that
may affect driving. While the benefits of antidepressants
outweigh their potential risks, prospective studies are
needed to better understand the risk of antidepressants
and depression on motor vehicle crashes. Of the seven
studies included in this analysis assessing the effects of
depression, only three (Sagberg, LeRoy and Sims) in-
cluded information on antidepressants. However, no
comparison of depression scores, medications use, and
crash risk in given individuals was reported. Equally, the
studies of the effects of antidepressants did not assess
the current or past levels of depression. Future studies
are needed to control for these interactions.
In addition to the effects of the drugs when taken
alone, antidepressants can interact with numerous clas-
ses of medications primarily due to their inhibition of
metablism of other drugs that are cleared through the
cytochrome P-450 system of enzymes. Drug interactions
may be especially important in impairing attention and
cognition when antidepressants are combined with
drugs that also have sedative properties, such as benzo-
diazepines and tricyclic antidepressants (TCAs). Among
antidepressants and their active metabolites, norfluoxe-
tine and fluvoxamine have significant inhibitory effects
on CYP 3A4 isoenzyme, which is the most abundant CYP
enzyme found in the human body (Greenblatt et al. 1999).
Fluoxetine and fluvoxamine have been reported to reduce
metabolism of multiple drugs, specifically the triazoloben-
zodiazepines (triazolam, alprazolam, and midazolam). By
blocking the metabolism of these benzodiazepines, the
serum concentrations of the benzodiazepines may increase
and have increased side effects (i.e. increased sedation,
dizziness, impaired cognition). It should be recognized that
although in vitro affinities of antidepressants for the
respective isoenzymes can be very helpful for predicting
potentially dangerous drug combinations, there is wide
variability between patients and their susceptibility for these
interactions. Much of this variability can be attributed to
genetic polymorphisms.
The strengths of this review include that 17 of the
studies reported used large population-based databases,
and 14 included detailed crash analysis, increasing the
validity of their findings. Also included were studies
from across a number of developed countries, with well-
designed studies that met the inclusion criteria. The
studies included in this review have several limitations.
The criteria for determination of depression ranged from
self-report to claims-based diagnostic codes. In deter-
mining the effects of depression and antidepressants, it
is difficult to distinguish effects of depression from
effects of drugs. The distinction is hampered by the
retrospective methodology of the majority of the studies.
Additionally, antidepressants are often prescribed with
other psychotropic medications, increasing the potential
for crashes due to both drugs, as has been demonstrated
in several studies (Rapoport et al. 2011).
Due to the limitation of these studies, the extent to
which antidepressants mitigate the effects of depression
remains unknown. However, the larger association of
depression with crash risk, vs. the use of antidepressants,
suggests that treatment of depression is likely to reduce
the risk. In the management of depression the risk-benefit
ratio fo treatment should be considered, as well as the side
effect profile when medications are being considered.
Conclusions
Based on the reports of the studies included in this ana-
lysis, depression and antidepressants pose a potential
hazard to driving safety. Physicians and other health pro-
viders, including pharmacists, should recognize the in-
herent risks of both the disorder and medications on
driving and educate their patients accordingly. More
research is needed to understand the individual contri-
butions of depression versus the medications used to
treat depression and to identify strategies to mitigate the
effect of both on driving safety.
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